• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.

作者信息

Prowse C V

机构信息

Scottish National Blood Transfusion Service, National Science Laboratory, Edinburgh, UK.

出版信息

Thromb Haemost. 1995 Oct;74(4):1191-6.

PMID:8560434
Abstract

In the therapy of factor VIII deficiency, experience has taught the value of achieving a target level of plasma coagulation factor VIII. There is a consensus that an empirical value of 2 iu/dl/iu/kg may be used to estimate recovery, and hence plasma levels, of factor VIII. This may be influenced by the methods used to assign label potency to the products and for assessment of patient post-infusion plasmas. To assess a possible influence of the standard used to assign product potency on in vivo recovery, a survey was undertaken of recent in vivo recovery studies. Analysis of submitted data, in combination with published studies over the last ten years, revealed a significant influence of the standard used to assign potency to products on the measured in vivo recovery. Furthermore, from limited data the potency determined in post-infusion patient plasmas was found not to be influenced by the use of one-stage or chromogenic assay methods.

摘要

相似文献

1
In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Thromb Haemost. 1995 Oct;74(4):1191-6.
2
Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.六种用于凝血因子VIII、凝血因子IX和血管性血友病因子的商业血浆参考品的比较。代表国际血栓与止血学会科学和标准化委员会凝血因子VIII和IX小组委员会。
Thromb Haemost. 1995 Sep;74(3):987-9.
3
Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.凝血因子 VIII 活性的凝血和显色测定:一般方面、标准化及建议。
Semin Thromb Hemost. 2002 Jun;28(3):247-56. doi: 10.1055/s-2002-32658.
4
Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.一种高纯度凝血因子VIII浓缩剂效价评估方法的验证——不同凝血因子VIII凝血活性测定方法的比较及预稀释剂的影响
Thromb Haemost. 1990 Oct 22;64(2):251-5.
5
A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.加拿大血友病A人群中标准贝塞斯达检测法与奈梅亨改良法在检测凝血因子VIII:C抑制剂方面性能的详细比较。加拿大血友病中心主任协会。国际血栓与止血学会科学与标准化委员会因子VIII/IX小组委员会。
Thromb Haemost. 1998 Apr;79(4):872-5.
6
Factor VIII concentrate for hemophilia: comparison of two heat-treated products.用于血友病的凝血因子 VIII 浓缩剂:两种热处理产品的比较。
CMAJ. 1987 Jan 15;136(2):150-2.
7
In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods.体内因子VIII的回收率:单阶段和双阶段测定方法的比较。
Thromb Haemost. 1979 Dec 21;42(4):1230-9.
8
[Results of in vivo analysis of injected fibrinogen degradation products and factor VIII in patients with hemophilia A].[血友病A患者注射纤维蛋白原降解产物和因子VIII的体内分析结果]
Z Gesamte Inn Med. 1978 Aug 1;33(15):525-9.
9
A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
Thromb Res. 2004;113(3-4):261-7. doi: 10.1016/j.thromres.2004.03.012.
10
Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
Am J Hematol. 1996 Mar;51(3):181-5. doi: 10.1002/(SICI)1096-8652(199603)51:3<181::AID-AJH1>3.0.CO;2-T.

引用本文的文献

1
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.F9 错义突变会损害因子 IX 的激活,与多种血浆表型相关。
J Thromb Haemost. 2022 Jan;20(1):69-81. doi: 10.1111/jth.15552. Epub 2021 Oct 24.
2
The History of Clotting Factor Concentrates Pharmacokinetics.凝血因子浓缩物药代动力学的历史
J Clin Med. 2017 Mar 20;6(3):35. doi: 10.3390/jcm6030035.